BIOA and BIOA-B Related Headlines
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA clears Leqembi Iqlik subcutaneous shot as Alzheimer's start dose
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
- Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
- Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
- FDA extends Leqembi Iqlik review period to August 24
- FDA extends Leqembi Iqlik review period to August 24
- Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
BIOA and BIOA-B Related Press Releases
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
- Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
- Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
- Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
